India, Aug. 17 -- 20/20 BioLabs, Inc. (AIDX), an AI-powered diagnostics company focused on early cancer and chronic disease detection, reported second-quarter 2026 results, with OneTest revenue rising 47% year over year and gross margin expanding significantly.
The company develops laboratory-based blood tests under its OneTest brand, including OneTest for Cancer, a multi-cancer early detection (MCED) blood test, and OneTest for Longevity, which measures inflammatory and cardiometabolic biomarkers.
Second Quarter Results
Total revenue increased 36.5% to $0.7 million, compared with $0.5 million in Q2 2025.
Revenue from the OneTest family increased 47.1% to $0.7 million and represented 95.3% of total revenue, compared with 88.4% in the pr...